Repligen Reports Q3 Revenue Growth, Raises 2026 Guidance

Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY, and raised 2026 guidance to $844M-$852M. GAAP net loss was $38.4M, while adjusted EPS was $0.53. The company completed its BioLife Solutions acquisition and opened a center in Seoul.

Original reporting
Published Oct 27, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen Reports Q3 Revenue Growth, Raises 2026 Guidance — source image
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The earnings release provides fresh guidance and confirms the acquisition, offering a clear catalyst for short‑term price movement.

02

Market read

The new guidance and acquisition completion are likely to drive immediate buying interest in RGEN.

03

What to watch

Potential dilution from the acquisition financing and macro‑economic headwinds for biotech spending.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Repligen (RGEN) is a U.S. biotech company focused on protein purification and cell‑therapy consumables. The BioLife Solutions acquisition expands its consumables platform.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 revenue of $209.3M, an 11% YoY increase, and raised full‑year 2026 revenue guidance to $844‑$852M after completing its BioLife Solutions acquisition.

Expected impact

upside pressure as the market prices in higher revenue outlook and synergies from the BioLife acquisition

Evidence & confidence

The earnings beat, revenue growth, and upward guidance are fresh primary disclosures that typically drive a positive price reaction.

Market effects

Biotech and biopharma sector may see modest uplift as Repligen's acquisition signals consolidation in cell‑therapy consumables.

U.S. biotech investors could adjust exposure to similar small‑cap biotech firms.

Limited to investors tracking U.S. biotech earnings and M&A activity.

Counterpoint

The net loss and integration risk could weigh on the stock if synergies take longer than expected.

Key entities

  • Repligen Corp.

    U.S. biotech firm reporting Q3 results and raising guidance.

  • BioLife Solutions

    Acquired consumables platform now part of Repligen.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.